coinfect
involv
porcin
reproduct
respiratori
syndrom
viru
prrsv
porcin
circoviru
type
contribut
group
diseas
syndrom
known
porcin
circovirusassoci
diseas
pcvad
presum
prrsv
infect
enhanc
replic
result
modul
host
immun
purpos
studi
evalu
replic
pathogenesi
pig
vaccin
prr
modifi
live
viru
mlv
vaccin
subsequ
challeng
combin
prrsv
earli
postchalleng
period
number
pig
prrsvassoci
clinic
sign
decreas
averag
daili
gain
adg
increas
vaccin
group
demonstr
protect
effect
prr
vaccin
howev
later
postchalleng
period
pig
vaccin
group
show
increas
viremia
decreas
adg
increas
pcvad
clinic
sign
increas
mortal
diseas
model
earli
benefit
prrsv
vaccin
outweigh
later
amplif
pcvad
citat
niederwerd
mc
bawa
b
nvl
tribl
br
kerrigan
lunney
jk
dekker
jcm
rowland
rrr
vaccin
porcin
reproduct
respiratori
syndrom
prr
modifi
live
viru
vaccin
follow
challeng
prr
viru
porcin
circoviru
type
protect
prr
enhanc
replic
pathogenesi
compar
result
nonvaccin
cochalleng
control
biosafeti
committe
studi
conduct
part
evalu
previous
describ
genom
marker
wur
popul
use
studi
compos
pig
two
genotyp
wur
genotyp
aa
wur
genotyp
ab
bb
ab
bb
genotyp
predict
benefici
effect
respons
prrsv
infect
vaccin
group
nonvaccin
group
balanc
accord
wur
genotyp
therefor
wur
factor
comparison
outcom
vaccin
nonvaccin
group
threeweekold
barrow
n
averag
age
day
obtain
highhealth
commerci
sourc
neg
prrsv
pig
deriv
sow
herd
previous
vaccin
capsid
subunit
vaccin
piglet
vaccin
obtain
wean
without
regard
matern
antibodi
level
pig
hous
two
environment
control
room
kansa
state
univers
larg
anim
research
center
maintain
biosafeti
level
condit
room
chemic
disinfect
clean
highheat
pressur
washer
ga
decontamin
vapor
hydrogen
peroxid
prior
use
room
empti
least
day
prior
start
studi
pig
hous
pen
area
ft
pig
per
pen
pig
given
access
food
water
ad
libitum
experiment
design
total
pig
randomli
alloc
two
ident
room
use
random
number
assign
protocol
hous
group
pig
per
pen
acclim
day
pig
one
room
vaccin
dose
commerci
prr
mlv
vaccin
ingelvac
prr
mlv
boehring
ingelheim
anim
health
genbank
access
administ
intramuscularli
accord
vaccin
label
instruct
day
postvaccin
dpv
pig
room
challeng
combin
prrsv
individu
bodi
weight
determin
day
postvaccin
blood
sampl
collect
pig
day
postinfect
dpi
blood
also
collect
vaccin
group
dpv
dpi
vaccin
nonvaccin
pig
randomli
select
human
euthanasia
complet
necropsi
perform
day
postinfect
pig
show
clinic
sign
pcvad
pig
show
sign
human
euthan
complet
necropsi
perform
pig
select
basi
clinic
diseas
without
regard
vaccin
statu
challeng
inoculum
prrsv
isol
use
prepar
inoculum
origin
deriv
lymph
node
pig
sever
pmw
describ
previous
prrsv
isol
genbank
access
isol
propag
cell
prrsv
compon
challeng
inoculum
share
ident
mlv
genbank
access
peptid
sequenc
level
sinc
wildtyp
genbank
access
propag
high
level
cell
cultur
took
advantag
heat
stabil
make
viru
prepar
lymph
node
suspens
enrich
suspens
heat
treat
min
remov
prrsv
bacteria
heatlabil
agent
treat
homogen
recombin
isol
prrsv
order
infect
cesareanderiv
colostrumdepriv
cdcd
pig
combin
lunglymph
node
homogen
prepar
cdcd
pig
prrsv
isol
homogen
method
describ
analysi
heattreat
prepar
common
agent
show
prepar
neg
heatstabl
agent
parvoviru
still
posit
torqu
teno
su
viru
ttsuv
porcin
oncoviru
pcov
ubiquit
titer
prrsv
determin
cell
briefli
viru
serial
dilut
minim
essenti
medium
mem
corn
supplement
fetal
bovin
serum
fb
sigmaaldrich
penicillinstreptomycin
pen
strep
uml
gml
respect
gibco
gml
amphotericin
b
fungizon
gibco
mm
prr
vaccin
enhanc
pcvad
p
orcin
circoviru
type
singlestrand
dna
viru
famili
circovirida
contribut
group
syndrom
collect
term
porcin
circovirusassoci
diseas
pcvad
two
import
clinic
syndrom
associ
pcvad
pneumonia
postwean
multisystem
wast
syndrom
pmw
manag
use
inactiv
subunit
vaccin
led
effect
control
pcvad
north
america
europ
howev
emerg
new
strain
lack
vaccin
program
countri
creat
uncertain
futur
continu
diseas
control
porcin
reproduct
respiratori
syndrom
viru
prrsv
singlestrand
rna
viru
famili
arterivirida
past
year
prrsv
remain
costli
diseas
affect
swine
product
worldwid
prrsv
infect
contribut
number
immunolog
outcom
increas
suscept
host
secondari
infect
primari
secondari
pathogen
prrsv
frequent
isol
along
one
major
cofactor
link
increas
replic
pathogenesi
previou
work
us
other
shown
princip
contribut
prrsv
increas
viremia
increas
replic
like
result
immun
stimul
result
cell
combin
prrsvinduc
immunomodul
complex
etiolog
pcvad
includ
role
prrsv
infect
yet
fulli
understood
extens
bodi
work
identifi
aberr
recognit
nonneutr
decoy
epitop
capsid
protein
cp
contribut
factor
pcvad
immunopathogenesi
natur
infect
popul
produc
mixtur
pig
recogn
decoy
neutral
epitop
may
explain
subpopul
infect
pig
goe
develop
pcvad
studi
took
advantag
host
genet
studi
evalu
clinic
virolog
outcom
experiment
challeng
prrsv
pig
without
prior
vaccin
commerci
prr
modifi
live
viru
mlv
result
demonstr
protect
properti
vaccin
howev
shortterm
benefit
outweigh
longerterm
impact
mlv
pcvad
anim
hous
experi
involv
anim
virus
perform
accord
guid
care
use
agricultur
anim
research
teach
feder
anim
scienc
societi
fass
usda
anim
welfar
act
anim
welfar
regul
approv
kansa
state
univers
institut
anim
care
use
committe
institut
hepe
life
technolog
dilut
ad
quadrupl
confluent
cell
tissu
cultur
plate
bd
falcon
follow
incub
co
well
examin
prrsvinduc
cytopath
effect
tissu
cultur
infecti
dose
tcid
per
millilit
calcul
use
method
reed
muench
quantiti
determin
titrat
swine
testicl
st
cell
briefli
serial
dilut
challeng
stock
plate
quadrupl
rapidli
divid
st
cell
tissu
cultur
plate
bd
falcon
dilut
prepar
eagl
minim
essenti
medium
emem
sigmaaldrich
supplement
fb
sigmaaldrich
gml
gentamicin
lonza
follow
incub
co
cell
fix
permeabil
aceton
stain
fluorescein
isothiocyan
fitc
label
porcin
antipcv
veterinari
medic
research
develop
inc
infect
cell
visual
use
invert
fluoresc
microscop
tcid
per
millilit
calcul
use
method
reed
muench
challeng
virus
recombin
yield
dose
consist
tcid
tcid
prrsv
mem
dose
split
ml
administ
intranas
remain
ml
administ
intramuscularli
clinic
evalu
pig
evalu
daili
presenc
clinic
sign
associ
pcvad
includ
dyspnea
aural
cyanosi
cough
nasal
discharg
openmouth
breath
poor
bodi
condit
muscl
wast
pallor
jaundic
lame
joint
effus
depress
lethargi
pig
visual
examin
veterinarian
veterinari
assist
day
studi
period
appropri
treatment
initi
pig
present
moder
sever
clinic
diseas
exampl
clinic
present
treatment
administ
includ
difficult
respir
ii
mucoid
nasal
discharg
iii
lame
associ
joint
effus
iv
pallor
jaundic
associ
muscl
wast
v
lethargi
depress
rectal
temperatur
clinic
affect
pig
antibiot
therapi
administ
includ
ceftiofur
hydrochlorid
respiratori
system
diseas
oxytetracyclin
infecti
arthriti
enrofloxacin
case
unrespons
previou
two
antibiot
pig
overt
clinic
diseas
rectal
temperatur
administ
flunixin
meglumin
nonsteroid
antiinflammatori
drug
nsaid
pig
intract
fever
day
durat
given
washout
period
administ
oral
meloxicam
treatment
administ
direct
veterinarian
clinic
sign
system
treatment
unrel
prrsv
pcvad
eg
lacer
dermat
hoof
wound
congenit
hernia
document
includ
data
analysi
relat
clinic
outcom
anim
human
euthan
pentobarbit
sodium
pig
die
human
euthan
due
circumst
unrel
effect
coinfect
exclud
mortal
analysi
averag
daili
gain
adg
calcul
chang
weight
divid
number
day
report
kilogram
per
day
gross
patholog
histopatholog
lung
remov
toto
immedi
euthanasia
gross
lung
lesion
score
use
two
techniqu
first
percentag
lung
affect
pneumonia
estim
dorsal
ventral
aspect
lung
lobe
gross
necropsi
result
report
percentag
whole
lung
affect
pneumonia
rang
second
dorsal
ventral
aspect
whole
lung
photograph
olympu
stylu
camera
digit
imag
evalu
gross
necropsi
use
photo
score
system
gross
anatom
photo
score
determin
scale
follow
macroscop
lesion
pneumonia
affect
gross
lung
pneumonia
affect
gross
lung
pneumonia
affect
gross
lung
pneumonia
affect
gross
lung
evalu
blind
sourc
lung
pictur
histopatholog
tissu
collect
lung
tracheobronchi
lymph
node
inguin
lymph
node
immedi
place
neutral
buffer
formalin
allow
fix
least
day
fix
tissu
process
autom
tissu
processor
embed
paraffin
slidemount
tissu
section
stain
hematoxylin
eosin
h
e
evalu
blind
boardcertifi
pathologist
microscop
lung
lesion
estim
base
follow
score
system
signific
microscop
lesion
mild
interstiti
pneumonia
lung
lobe
involv
mild
moder
multifoc
interstiti
pneumonia
lung
lobe
involv
moder
sever
multifoc
interstiti
pneumonia
lung
lobe
involv
sever
diffus
interstiti
pneumonia
lung
lobe
involv
final
score
assign
pig
averag
two
separ
evalu
pathologist
remain
blind
sourc
lung
tissu
immunohistochem
ihc
stain
antigen
stain
paraffinembed
thin
section
tissu
perform
personnel
kansa
state
veterinari
diagnost
laboratori
briefli
deparaffin
slidemount
thin
section
first
treat
proteinas
k
mgml
dilut
bond
enzym
diluent
proclin
min
room
temperatur
bond
enzym
pretreat
kit
leica
biosystem
rabbit
antibodi
iowa
state
univers
dilut
bond
primari
antibodi
diluent
leica
biosystem
appli
tissu
section
min
room
temperatur
bound
antibodi
detect
incub
gml
polyap
antirabbit
igg
leica
biosystem
antibodi
diluent
min
room
temperatur
complex
visual
use
fast
red
chromogen
bond
polym
refin
red
detect
kit
leica
biosystem
counterstain
hematoxylin
measur
prrsv
viremia
viral
dna
rna
extract
simultan
l
serum
use
ambion
viral
isol
kit
appli
biosystem
accord
manufactur
instruct
prr
viral
rna
quantifi
use
ezprrsv
mpx
realtim
revers
transcriptionpcr
rtpcr
targetspecif
reagent
tetracor
accord
manufactur
instruct
consist
plate
contain
tetracor
quantif
standard
control
set
use
ezprrsv
mpx
rtpcr
reagent
pcr
carri
touch
realtim
pcr
detect
system
biorad
format
use
recommend
cycl
paramet
dna
quantifi
use
ssoadvanc
univers
sybr
green
supermix
biorad
forward
revers
pcr
primer
respect
primer
use
final
concentr
nucleasefre
water
use
bring
master
mix
volum
l
per
reaction
addit
l
templat
nucleic
acid
brought
final
reaction
volum
sampl
l
standard
curv
posit
neg
control
includ
plate
plasmid
dna
use
standard
curv
positivecontrol
templat
dna
insert
plasmid
obtain
field
strain
plasmid
dna
isol
use
pureyield
plasmid
miniprep
system
promega
accord
manufactur
instruct
dna
standard
curv
quantifi
use
nanodrop
spectrophotomet
standard
curv
produc
dilut
purifi
plasmid
dna
nucleasefre
water
follow
five
serial
dilut
nucleasefre
water
final
standard
curv
contain
point
rang
copi
templat
dna
produc
threshold
cross
valu
cycl
standard
curv
run
duplic
nucleasefre
water
neg
control
pcr
carri
touch
realtim
pcr
detect
system
use
follow
set
activ
min
follow
cycl
denatur
annealingextens
melt
curv
perform
use
increment
pcr
assay
result
report
log
prrsv
rna
start
quantiti
copi
number
per
reaction
volum
log
dna
start
quantiti
per
reaction
volum
capsid
protein
cp
polypeptid
fragment
cp
cp
clone
express
escherichia
coli
vector
phue
describ
previous
protein
express
bacteria
grown
luriabertani
lb
broth
plu
ampicillin
mgml
incub
shake
optic
densiti
nm
od
reach
protein
express
induc
isopropyl
iptg
final
concentr
mm
bacteria
harvest
h
later
protein
purifi
use
usb
prepeas
histidinetag
protein
purif
kit
affymetrix
nondenatur
condit
accord
manufactur
direct
puriti
assess
sdspage
total
protein
measur
use
biorad
protein
assay
protein
coupl
carboxyl
luminex
magplex
polystyren
microspher
accord
manufactur
direct
assay
approxim
antigenco
bead
suspend
l
phosphatebuff
salin
goat
serum
pbsg
place
well
roundbottom
polystyren
plate
costar
sera
dilut
pbsg
l
ad
well
plate
wrap
foil
incub
min
room
temperatur
gentl
shake
plate
place
magnet
bead
wash
three
time
l
pbsg
detect
igg
l
biotinspconjug
affinitypurifi
goat
antiswin
secondari
antibodi
igg
jackson
immunoresearch
dilut
gml
pbsg
l
ad
well
plate
incub
room
temperatur
min
wash
three
time
follow
addit
l
streptavidinconjug
phycoerythrin
sape
gml
pbsg
min
plate
wash
microspher
resuspend
l
pbsg
microspher
analyz
use
magpix
instrument
luminex
luminex
xponent
softwar
version
minimum
microspher
use
calcul
mean
fluoresc
intens
mfi
sampletoposit
sp
ratio
calcul
mfi
sampl
mfi
neg
control
mfi
standard
posit
control
mfi
neg
control
statist
analys
logist
mix
model
use
evalu
effect
vaccin
binari
trait
blue
ear
veterinari
treatment
pcvad
mortal
model
includ
design
effect
vaccin
wur
interact
vaccin
wur
initi
bodi
weight
covari
random
effect
includ
sire
dam
pen
odd
ratio
effect
vaccin
estim
vaccin
group
nonvaccin
group
treatment
mortal
nonvaccin
group
vaccin
group
blue
ear
odd
ratio
includ
wald
confid
interv
ci
data
percentag
lung
lobe
involv
analyz
normal
quantit
respons
variabl
wherea
gross
anatom
photo
score
microscop
lung
lesion
score
analyz
ordin
categor
variabl
mix
multinomi
regress
model
includ
fix
effect
prr
vaccin
wur
interact
clinic
sign
presenceabs
sire
dam
includ
random
effect
analys
perform
use
glimmix
procedur
sa
version
statist
analysi
system
institut
inc
comparison
averag
daili
gain
viremia
antibodi
respons
group
perform
use
graphpad
prism
softwar
version
use
unpair
test
viremia
increas
prr
mlv
replic
vaccin
group
prior
challeng
assess
rtpcr
serum
sampl
collect
dpv
pig
sera
test
detect
level
vaccin
viru
confirm
pig
support
activ
mlv
replic
fig
mean
level
viremia
dpv
log
templat
per
pcr
prior
challeng
nonvaccin
group
neg
prrsv
nucleic
acid
serum
data
shown
result
prrsv
viremia
challeng
shown
fig
prrsv
infect
nonvaccin
group
follow
typic
cours
viremia
peak
dpi
follow
decay
eventu
disappear
viru
blood
dpi
vaccin
group
pig
detect
level
viru
nucleic
acid
serum
day
vaccin
time
challeng
prrsv
viremia
vaccin
group
peak
day
challeng
decay
except
day
challeng
day
mean
prrsv
level
significantli
lower
day
vaccin
group
fig
peak
viremia
vaccin
group
day
reduc
log
unit
nonvaccin
pig
result
demonstr
vaccin
effect
reduc
prr
viremia
heterolog
challeng
model
mean
viremia
level
vaccin
nonvaccin
group
present
fig
nonvaccin
group
mean
viremia
peak
day
challeng
remain
elev
remaind
studi
contrast
mean
viremia
vaccin
group
peak
dpi
mean
viru
level
approxim
log
unit
greater
vaccin
group
nonvaccin
group
p
thu
viremia
vaccin
group
peak
much
earlier
immun
dam
provid
temporari
protect
piglet
infect
howev
day
wean
passiv
immun
decay
point
pig
becom
suscept
viru
normal
present
environ
time
challeng
low
detect
level
nucleic
acid
present
vaccin
pig
nonvaccin
pig
mean
viremia
level
prior
challeng
log
templat
per
pcr
pcrposit
vaccin
nonvaccin
pig
respect
increas
proport
nonvaccin
pig
evid
exposur
prior
challeng
may
account
differ
outcom
two
group
howev
exclus
pig
alter
conclus
studi
prrsv
vaccin
result
reduc
clinic
sign
patholog
first
day
coinfect
prior
viru
challeng
clinic
sign
appar
either
vaccin
nonvaccin
group
infect
two
clinic
syndrom
emerg
first
prrsvassoci
syndrom
aural
cyanosi
commonli
known
blue
ear
easili
identifi
pig
presenc
red
cyanot
blue
discolor
ear
tissu
even
though
blue
ear
pathognomon
prr
often
coincid
acut
infect
repres
exampl
pig
blue
ear
shown
fig
blue
ear
observ
among
either
vaccin
nonvaccin
pig
prior
challeng
howev
postchalleng
period
pig
document
blue
ear
one
day
shown
fig
percentag
pig
blue
ear
peak
dpi
correspond
peak
prr
viremia
compar
fig
overal
vaccin
pig
nonvaccin
pig
document
blue
ear
nonvaccin
pig
time
ci
like
develop
blue
ear
vaccin
pig
p
total
number
day
blue
ear
vaccin
nonvaccin
group
respect
reduct
number
pig
blue
ear
vaccin
group
consist
benefici
effect
prr
mlv
primari
clinic
sign
associ
acut
prrsv
infect
respiratori
diseas
result
interstiti
pneumonia
lung
remov
euthan
pig
pig
group
randomli
select
dpi
figur
show
summari
gross
microscop
lung
score
mean
score
percentag
gross
lung
lobe
involv
microscop
score
interstiti
pneumonia
higher
nonvaccin
group
howev
differ
statist
signific
p
percentag
lung
involv
histopatholog
score
togeth
result
show
vaccin
prr
mlv
overal
protect
effect
reduc
prrsv
viremia
decreas
prrsassoci
clinic
sign
beyond
acut
period
infect
second
clinic
syndrom
appear
first
becam
appar
increas
number
pig
receiv
system
veterinari
treatment
due
clinic
sign
associ
pcvad
tachypnea
dyspnea
pyrexia
loss
condit
muscl
wast
mucoid
nasal
discharg
lethargi
pallor
jaundic
fig
lesion
typic
pcvad
found
gross
anatom
microscop
examin
lung
lymph
node
pig
die
euthan
repres
pictur
photomicrograph
show
lesion
associ
clinic
affect
pig
present
fig
lung
show
multifoc
diffus
interstiti
pneumonia
mottl
lung
tissu
hemorrhag
consolid
fig
microscop
level
multifoc
diffus
interstiti
pneumonia
lymphohistiocyt
infiltr
alveolar
septa
peribronchiolar
area
easili
visibl
fig
lymph
node
affect
pig
show
deplet
lymphocyt
fig
posit
stain
antigen
observ
lymph
node
lung
affect
pig
fig
analysi
gross
microscop
lesion
combin
accumul
antigen
target
organ
confirm
presenc
pcvad
number
pig
undergo
treatment
result
pcvadassoci
clinic
sign
peak
dpi
fig
four
pig
human
euthan
initi
treatment
due
sever
clinic
present
declin
percentag
pig
pcvad
clinic
sign
larg
result
increas
mortal
euthan
pig
moribund
nonrespons
treatment
compar
fig
c
entir
studi
period
pig
receiv
least
day
system
veterinari
treatment
nonvaccin
group
vaccin
group
vaccin
pig
time
ci
like
receiv
veterinari
treatment
nonvaccin
pig
p
entir
studi
period
macroscop
microscop
chang
organ
tissu
evalu
dpi
clinic
affect
pig
human
euthan
result
failur
respond
treatment
comparison
pig
without
clinic
sign
also
necropsi
summar
tabl
pig
clinic
sign
show
form
macroscop
lung
involv
determin
photograph
score
macroscop
score
group
without
clinic
sign
significantli
lower
p
similar
trend
clinic
affect
versu
nonaffect
pig
appear
microscop
level
howev
differ
statist
signific
p
mild
sever
lymphoid
deplet
observ
pig
clinic
sign
compar
pig
without
clinic
sign
even
though
pig
without
clinic
sign
appear
normal
almost
show
form
patholog
relat
pcvad
mild
moder
pneumonia
andor
mild
lymphoid
deplet
effect
prr
mlv
vaccin
mortal
shown
fig
nonvaccin
pig
die
result
overal
surviv
rate
vaccin
pig
die
overal
surviv
rate
fig
vaccin
pig
time
ci
like
die
overal
studi
period
nonvaccin
pig
p
increas
mortal
becam
appar
day
associ
appear
pcvad
pig
develop
clinic
sign
ten
vaccin
pig
fill
bar
nonvaccin
pig
shade
bar
randomli
remov
studi
day
assess
pneumonia
result
mean
standard
deviat
present
percentag
gross
lung
involv
histopatholog
score
differ
vaccin
nonvaccin
group
signific
p
pcvad
die
prior
end
studi
vaccin
nonvaccin
result
mortal
rate
approxim
pig
exhibit
clinic
sign
dpi
vaccin
pig
time
ci
like
die
nonvaccin
pig
p
even
though
mortal
higher
vaccin
group
differ
vaccin
nonvaccin
group
significantli
differ
vaccin
increas
appear
antibodi
decoy
epitop
previou
work
identifi
presenc
antibodi
decoy
epitop
capsid
protein
cp
correl
pcvad
presenc
anticp
respons
associ
absenc
neutral
activ
serum
pig
vaccin
protect
diseas
produc
littl
anticp
activ
preferenti
recogn
larger
epitop
cp
pig
natur
infect
show
mixtur
two
antibodi
respons
mean
standard
result
across
plate
antibodi
respons
vaccin
nonvaccin
group
present
cp
cp
ratio
higher
ratio
immun
respons
skew
toward
recognit
decoy
epitop
result
present
fig
show
signific
p
differ
cp
cp
mean
ratio
non
vaccin
pig
versu
vaccin
pig
exclus
pig
show
presenc
nucleic
acid
time
challeng
chang
ratio
affect
conclus
cp
cp
mean
ratio
nonvaccin
pig
n
vaccin
pig
n
p
discuss
previou
work
show
pig
low
cp
cp
ratio
protect
diseas
therefor
nonvaccin
pig
ratio
n
compar
nonvaccin
pig
antibodi
ratio
n
pig
antibodi
ratio
significantli
lower
level
circul
serum
p
p
p
p
dpi
pig
higher
ratio
result
confirm
earlier
find
describ
nonprotect
effect
anticp
antibodi
effect
prr
mlv
vaccin
adg
entir
studi
period
mean
averag
daili
gain
adg
vaccin
group
n
kg
compar
kg
nonvaccin
group
n
mean
differ
significantli
two
group
p
decreas
mean
adg
also
observ
vaccin
group
postviru
challeng
period
howev
differ
vaccin
group
adg
kg
n
nonvaccin
group
adg
kg
n
statist
signific
p
addit
adg
differ
two
group
studi
period
longer
signific
exclus
pig
detect
prior
challeng
therefor
moredetail
analysi
conduct
calcul
adg
weekli
basi
fig
result
show
adg
differ
nonvaccin
vaccin
group
could
divid
three
distinct
phase
first
phase
cover
prechalleng
period
mean
adg
vaccin
reduc
signific
differ
vaccin
nonvaccin
group
appear
week
vaccin
second
phase
cover
period
acut
prrsv
infect
week
viru
challeng
mean
adg
significantli
increas
vaccin
group
adg
remain
higher
vaccin
group
second
week
postchalleng
differ
signific
improv
adg
vaccin
pig
like
result
posit
effect
vaccin
reduc
prrsassoci
clinic
sign
viru
load
fig
third
phase
cover
period
onset
pcvad
begin
week
viru
challeng
end
studi
phase
adg
lower
vaccin
group
everi
time
point
significantli
lower
mean
adg
valu
week
viru
challeng
signific
decreas
adg
also
initi
detect
vaccin
pig
week
postchalleng
howev
differ
longer
signific
pig
exclud
p
lower
mean
adg
valu
consist
effect
pcvad
includ
poor
growth
perform
muscl
wast
neg
effect
vaccin
adg
could
result
increas
number
pig
clinic
appar
pcvad
therefor
separ
analysi
perform
pig
clinic
sign
surviv
length
studi
exclud
vaccin
nonvaccin
group
remov
pig
clinic
sign
increas
adg
two
group
kg
nonvaccin
pig
without
clinic
sign
n
kg
vaccin
pig
without
clinic
sign
n
p
howev
even
absenc
overt
clinic
sign
prrsv
vaccin
neg
effect
weight
gain
enhanc
infect
lead
pcvad
typic
associ
immun
stimul
replic
locat
nuclei
permiss
cell
depend
cellular
enzym
express
phase
cell
cycl
presum
activ
divid
lymphocyt
respons
immun
stimulu
provid
cellular
environ
ideal
support
replic
prrsv
porcin
parvoviru
mycoplasma
hyopneumonia
common
copathogen
link
lymphoprolifer
increas
pathogenesi
exampl
noninfecti
immunostimul
includ
immun
keyhol
limpet
hemocyanin
incomplet
freund
adjuv
inactiv
vaccin
mycoplasma
hyopneumonia
actinobacillu
pleuropneu
monia
result
studi
show
prr
mlv
initi
benefici
effect
reduc
prrsassoci
clinic
sign
prr
viremia
howev
prrsvvaccin
pig
show
increas
replic
reduc
averag
daili
gain
increas
clinic
sign
associ
pcvad
previou
experiment
studi
document
interact
prr
mlv
infect
yield
conflict
result
allan
et
al
found
colostrumdepriv
specificpathogenfre
spf
pig
infect
age
week
administ
prr
mlv
week
later
greater
amount
antigen
tissu
moresever
histolog
lesion
characterist
pmw
pig
infect
alon
howev
pig
fail
exhibit
clinic
sign
gross
lesion
typic
pcvad
contrast
opriessnig
et
al
evalu
effect
infect
efficaci
prr
mlv
group
earlywean
spf
pig
pig
inocul
age
week
vaccin
prr
mlv
week
later
challeng
prrsv
age
week
group
mlv
exhibit
lower
adg
moresever
lung
lesion
prrsv
challeng
group
vaccin
receiv
prrsv
challeng
without
detect
affect
lung
ihc
author
attribut
lesion
prrsv
infect
conclud
effect
reduc
efficaci
prr
mlv
park
et
al
investig
potenti
prr
mlv
reduc
prrsvassoci
amplif
pathogenesi
coinfect
prrsv
group
convent
pig
subject
varieti
treatment
involv
differ
combin
prr
mlv
wildtyp
prrsv
vaccin
pig
vaccin
prr
mlv
subunit
vaccin
challeng
week
later
prrsv
group
receiv
prr
mlv
follow
coinfect
show
differ
viremia
patholog
number
cell
lymph
node
lung
coinfect
group
vaccin
prr
mlv
contrast
studi
vaccin
enhanc
pcvad
author
found
coinfect
pig
without
previou
prr
mlv
vaccin
similar
replic
pathogenesi
field
studi
also
yield
conflict
result
survey
conduct
pig
farm
netherland
includ
question
regard
prr
mlv
use
farm
without
pmw
pcvad
result
show
prr
mlv
signific
risk
factor
pmw
outbreak
contrast
analysi
effect
prr
mlv
farm
affect
pcvad
unit
state
found
farm
incorpor
prr
mlv
significantli
lower
level
viremia
nonvaccin
farm
age
group
peak
wast
diseas
occur
studi
quantit
pcr
qpcr
use
measur
serum
sampl
collect
differ
time
point
herd
vaccin
prr
mlv
nonvaccin
herd
result
suggest
prr
mlv
reduc
viremia
failur
experiment
studi
find
consist
link
prr
mlv
pcvad
like
due
part
length
observ
period
exampl
studi
describ
termin
day
infect
day
challeng
prrsv
current
studi
peak
pcvad
occur
day
challeng
prrsv
anoth
import
differ
size
experiment
group
typic
preval
clinic
ill
pig
farm
affect
pcvad
small
group
pig
anim
clinic
diseas
may
appar
present
current
studi
util
pig
mimick
environ
found
field
provid
depth
data
requir
observ
quantif
lowpercentag
outcom
pcvad
morbid
rate
nonvaccin
vaccin
pig
respect
therefor
pcvad
assess
compar
mortal
rate
clinic
diseas
present
viremia
weight
gain
rel
larg
group
evalu
sever
week
infect
larg
group
pig
requir
ensur
clinic
diseas
express
control
group
includ
pig
challeng
prrsv
alon
incorpor
studi
design
therefor
conclus
base
find
vaccin
nonvaccin
cochalleng
pig
caution
exercis
gener
result
singl
infect
ie
effect
prr
mlv
pig
ubiquit
swine
popul
elimin
viru
environ
extrem
difficult
demonstr
studi
pig
detect
serum
time
challeng
although
pig
minor
group
titer
rel
low
log
templat
per
pcr
vaccin
nonvaccin
pig
respect
presenc
prior
challeng
consid
possibl
factor
postchalleng
respons
especi
true
due
differ
proport
pig
two
group
despit
random
alloc
pig
balanc
genotyp
differ
like
due
failur
random
distribut
pig
equal
across
two
group
therefor
analys
also
complet
initi
posit
pig
exclud
conclus
studi
confirm
regardless
highlight
difficulti
elimin
environ
also
suggest
pig
balanc
accord
statu
prior
challeng
significantli
increas
level
viremia
prr
mlvtreat
pig
observ
day
challeng
later
time
point
fig
effect
prr
mlv
infect
similar
seen
previou
studi
us
show
signific
increas
level
viremia
day
coinfect
prrsv
current
studi
noteworthi
viremia
level
differ
significantli
vaccin
nonvaccin
group
peak
pcvad
howev
clinic
ill
pig
maintain
significantli
higher
level
p
circul
later
time
point
dpi
data
shown
increas
incid
pcvad
vaccin
pig
dpi
may
also
result
greater
level
local
tissu
studi
need
assess
differ
quantiti
tissu
distribut
vaccin
nonvaccin
pig
averag
daili
gain
adg
use
swine
product
object
measur
overal
health
perform
neg
effect
prr
mlv
growth
perform
well
document
exampl
opriessnig
et
al
report
pig
vaccin
prr
mlv
age
week
exhibit
significantli
lower
adg
nonvaccin
pig
pretzer
et
al
found
prr
mlvvaccin
wean
pig
lower
adg
dpv
nonvaccin
pig
effect
adg
longer
appar
dpv
vaccin
pig
maintain
lighter
weight
overal
confirm
neg
effect
prr
mlv
adg
period
prior
coinfect
significantli
reduc
adg
observ
third
week
vaccin
fig
benefit
prrsv
vaccin
document
first
week
prrsv
challeng
mlv
posit
effect
adg
although
vaccin
pig
studi
increas
adg
first
week
postchalleng
effect
quickli
outweigh
adg
decreas
presenc
pcvad
vaccin
decreas
adg
clinic
affect
pig
pig
without
clinic
sign
studi
period
demonstr
poor
growth
perform
may
subclin
manifest
pcvad
appar
healthi
pig
least
three
mechan
may
involv
enhanc
pcvad
follow
prrsv
vaccin
first
prr
mlv
may
function
stimul
immun
system
increas
number
cell
wildtyp
virus
lymphocyt
undergo
mitosi
respons
vaccin
prr
mlv
therebi
increas
popul
cell
abil
support
replic
addit
vaccin
like
stimul
prrsvspecif
lymphocyt
popul
restimul
challeng
wildtyp
prrsv
second
like
wildtyp
prr
virus
prr
mlv
may
suppress
innat
immun
therebi
block
respons
exampl
prrsv
nonstructur
protein
block
induct
interferon
respons
cell
interferon
viral
protein
antagon
type
interferon
respons
degrad
key
compon
need
interferon
gene
express
inhibit
interferon
signal
pathway
final
third
mechan
base
possibl
prr
mlv
may
skew
immun
respons
toward
product
nonneutr
antibodi
circul
swine
popul
least
year
emerg
north
america
attribut
outbreak
pcvad
sinc
diseas
effect
manag
use
vaccin
therefor
neg
effect
mlv
infect
may
relev
howev
remain
sever
countri
prr
mlv
vaccin
wide
use
absenc
comprehens
pcvad
vaccin
program
potenti
new
emerg
strain
escap
current
vaccin
protect
emerg
mutant
strain
document
china
recent
associ
pcvad
outbreak
vaccin
herd
unit
state
korea
overal
studi
support
notion
maintain
success
control
program
assess
risk
virul
prrsv
exposur
critic
weigh
benefit
prr
mlv
